These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 22653805)
1. Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Austin PC; Anderson GM; Cigsar C; Gruneir A Pharmacoepidemiol Drug Saf; 2012 Jul; 21(7):714-724. PubMed ID: 22653805 [TBL] [Abstract][Full Text] [Related]
3. Validating an approach to overcome the immeasurable time bias in cohort studies: a real-world example and Monte Carlo simulation study. Oh IS; Jeong HE; Lee H; Filion KB; Noh Y; Shin JY Int J Epidemiol; 2023 Oct; 52(5):1534-1544. PubMed ID: 37172269 [TBL] [Abstract][Full Text] [Related]
4. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. Uddin MJ; Groenwold RH; de Boer A; Belitser SV; Roes KC; Hoes AW; Klungel OH Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):165-77. PubMed ID: 24306965 [TBL] [Abstract][Full Text] [Related]
5. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs. Nicholas JM; Grieve AP; Gulliford MC J Clin Epidemiol; 2012 Apr; 65(4):384-93. PubMed ID: 22197519 [TBL] [Abstract][Full Text] [Related]
6. The performance of different propensity-score methods for estimating relative risks. Austin PC J Clin Epidemiol; 2008 Jun; 61(6):537-45. PubMed ID: 18471657 [TBL] [Abstract][Full Text] [Related]
7. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. Takeuchi Y; Shinozaki T; Matsuyama Y BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575 [TBL] [Abstract][Full Text] [Related]
8. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Mi X; Hammill BG; Curtis LH; Lai EC; Setoguchi S Stat Med; 2016 Nov; 35(26):4824-4836. PubMed ID: 27350312 [TBL] [Abstract][Full Text] [Related]
9. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines. Li W; Chen C; Li X; Beckman RA Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586 [TBL] [Abstract][Full Text] [Related]
10. Effect of exposure misclassification on the mean squared error of population attributable risk and prevented fraction estimates. Walter SD; Hsieh CC; Liu Q Stat Med; 2007 Nov; 26(26):4833-42. PubMed ID: 17691081 [TBL] [Abstract][Full Text] [Related]
11. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs. Colditz GA Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580 [TBL] [Abstract][Full Text] [Related]
12. A comparison of methods to estimate the hazard ratio under conditions of time-varying confounding and nonpositivity. Naimi AI; Cole SR; Westreich DJ; Richardson DB Epidemiology; 2011 Sep; 22(5):718-23. PubMed ID: 21747286 [TBL] [Abstract][Full Text] [Related]
13. Using the entire history in the analysis of nested case cohort samples. Rivera CL; Lumley T Stat Med; 2016 Aug; 35(18):3213-28. PubMed ID: 26910486 [TBL] [Abstract][Full Text] [Related]
14. Precision of maximum likelihood estimation in adaptive designs. Graf AC; Gutjahr G; Brannath W Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506 [TBL] [Abstract][Full Text] [Related]
15. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Austin PC Stat Med; 2010 Sep; 29(20):2137-48. PubMed ID: 20108233 [TBL] [Abstract][Full Text] [Related]
16. A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men. Shiels MS; Cole SR; Chmiel JS; Margolick J; Martinson J; Zhang ZF; Jacobson LP J Clin Epidemiol; 2010 Apr; 63(4):459-67. PubMed ID: 19880284 [TBL] [Abstract][Full Text] [Related]
17. When should case-only designs be used for safety monitoring of medical products? Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593 [TBL] [Abstract][Full Text] [Related]
18. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups. Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357 [TBL] [Abstract][Full Text] [Related]
19. Sampling designs for rare time-dependent exposures: a comparison of the nested exposure case-control design and exposure density sampling. Feifel J; von Cube M; Ohneberg K; Ershova K; Wolkewitz M; Beyersmann J; Schumacher M Epidemiol Infect; 2021 Apr; 149():e122. PubMed ID: 33888170 [TBL] [Abstract][Full Text] [Related]
20. Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. Franklin JM; Eddings W; Austin PC; Stuart EA; Schneeweiss S Stat Med; 2017 May; 36(12):1946-1963. PubMed ID: 28208229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]